Last reviewed · How we verify
NCT06839014
Exercise Therapy in Head and Neck Squamous Cell Carcinoma (HNSCC)
NA trial testing Exercise in Head and Neck Squamous Cell Carcinoma HNSCC in 40 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Our Lady of the Lake Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 April 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Exercise
Conditions studied
- Head and Neck Squamous Cell Carcinoma HNSCC — all drugs for Head and Neck Squamous Cell Carcinoma HNSCC →
Sponsor
Our Lady of the Lake Hospital
Who can join
18 and older, any sex, with Head and Neck Squamous Cell Carcinoma HNSCC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goals of this clinical trial are to learn 1. Determine the feasibility of a home-based exercise analog therapy using Transcutaneous Electrical Nerve Stimulation (TENS), 2. Determine the effects of exercise analog therapy on muscle mass, strength, and clinical outcomes, and 3. Determine the effects of exercise analog therapy on immune phenotype and inflammation response in patients undergoing radiation for head and neck squamous cell carcinoma (HNSCC). The main question it aims to answer are: Does an exercise regimen using an analog TENS unit during the course of cancer treatment for those with HNSCC improve muscle mass, strength, clinical outcomes and immune response compared to those that do not perform the exercise regimen during their cancer treatment? Researchers will compare outcomes of patients undergoing cancer treatment + TENS unit exercise to those being treated for their cancer with no exercise TENS unit. In the exercise arm, subjects will use the TENS unit for 30 minutes of exercise a day, 3 times a week for the extent of their cancer treatments. Weekly check-ins by phone or less frequently at scheduled in person visits. Participants will keep a log of their exercise sessions to make sure that the exercise occurs 3 times a week for 30 minutes each and note any reasons why a session may have been missed or time shortened. Both arms will have a blood draw at the beginning of their cancer treatment and approximately 4 weeks after the last cancer treatment (\~40mL). These samples will be tested for molecules that signal a higher or lower immune response with the addition of the exercise in one group compared to the cancer therapy only group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06839014
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exercise
Trials testing the same drug.
- NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
- NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
- NCT07589725 — Mulligan Mobilization in Lateral Elbow Tendinopathy · NA · not yet recruiting
- NCT07524400 — Effects of Physical Exercise Combined With Transcranial Direct Current Stimulation in Parkinson's Disease · NA · recruiting
- NCT06627569 — Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans · NA · not yet recruiting
Other recruiting trials for Head and Neck Squamous Cell Carcinoma HNSCC
Currently open trials in the same condition.
- NCT07457281 — GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Stu · Phase 1 · recruiting
- NCT07190755 — Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinom · NA · recruiting
Other Our Lady of the Lake Hospital trials
Trials by the same sponsor.
- NCT06659458 — Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients · recruiting
- NCT05993039 — Inhalational Anesthesia vs TIVA in Endoscopic Tympanoplasty · EARLY_PHASE1 · unknown
- NCT05639686 — TIVA vs TXA in Sinus Surgery to Evaluate Operative Blood Loss and Surgical Field Quality · NA · unknown
- NCT04794842 — Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection · EARLY_PHASE1 · unknown
- NCT04710719 — Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06839014 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Our Lady of the Lake Hospital
- Last refreshed: 25 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06839014.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing